Mitochondrial Glutathione Fuels Breast Cancer Spread to the Lung
A new study shows mitochondrial glutathione import via SLC25A39 is essential for breast cancer metastasis, acting through stress-response signaling.
Summary
Researchers discovered that breast cancer cells accumulating mitochondrial glutathione (GSH) via the transporter SLC25A39 gain a critical advantage during lung metastasis. Using mitochondrial metabolomics, genetic screens, and patient-derived models, they showed that SLC25A39 loss blocks metastatic colonization without affecting primary tumor growth. Conversely, boosting mitochondrial GSH accelerated metastasis. The mechanism involves ATF4, a stress-response transcription factor: SLC25A39 is required for optimal ATF4 activation under hypoxia and stress, linking mitochondrial GSH availability to adaptive signaling during early colonization. These findings position mitochondrial GSH as a limiting, druggable metabolite in metastatic breast cancer.
Detailed Summary
Metastasis remains the primary cause of cancer mortality, yet the specific metabolic adaptations cancer cells require to colonize distant organs are poorly understood. This study addressed that gap by focusing on mitochondrial metabolism in breast cancer metastasis, revealing a previously unrecognized role for mitochondrial glutathione (GSH) in enabling lung colonization.
The researchers used a mitochondrial metabolomics strategy based on an immunoprecipitable mitochondrial tag (mitotag) expressed in 4T1 murine breast cancer cells. By comparing mitochondrial metabolite profiles from primary mammary tumors and lung metastases in vivo, they identified GSH as one of the most significantly upregulated mitochondrial metabolites in metastatic tumors. Elevated GSH accumulation was driven by increased expression of SLC25A39, the principal mitochondrial GSH transporter.
To confirm functional importance, the team conducted CRISPR loss-of-function screens using a custom sgRNA library targeting 236 mitochondrial membrane proteins in the highly aggressive MDA-MB-231 (LM2) cell line. SLC25A39 emerged as selectively essential for metastasis but dispensable for primary tumor growth. This was validated across multiple human and murine breast cancer models (MDA-MB-231, 4T1, HCC1806), patient-derived xenograft organoids, and orthotopic tumor resection experiments. Critically, a transport-deficient SLC25A39 mutant failed to rescue metastatic capacity, while expression of a mitochondrially targeted bacterial GSH-synthesizing enzyme (mito-GshF) fully restored metastasis in SLC25A39 knockout cells, confirming that mitochondrial GSH itself—not another transported metabolite—is the key factor.
Temporal experiments using doxycycline-inducible SLC25A39 knockdown pinpointed the requirement for mitochondrial GSH to early post-extravasation colonization, not during circulation or extravasation. Spatial metabolomics confirmed elevated GSH specifically within early metastatic nodules in the lung. Gain-of-function experiments showed that overexpressing SLC25A39 or mito-GshF accelerated metastasis and reduced mouse survival, establishing mitochondrial GSH as a limiting factor actively selected for during cancer progression. Clinical data reinforced this: immunohistochemistry showed higher SLC25A39 staining in metastatic versus primary breast tumors, and higher SLC25A39 expression correlated with worse overall survival.
To uncover how mitochondrial GSH promotes colonization, the team performed CRISPR activation screens in SLC25A39-deficient cells and identified ATF4—a master transcription factor of the integrated stress response (ISR)—as a bypass mechanism capable of restoring metastatic potential. Mechanistically, SLC25A39 loss impaired ATF4 activation under hypoxic and metabolic stress conditions encountered during early colonization, linking mitochondrial GSH availability directly to ISR signaling. This is distinct from the classical antioxidant function of GSH, as ROS manipulation alone did not recapitulate the metastatic phenotype. Together, the findings identify a novel mitochondrial GSH–ISR axis as a critical and potentially druggable pathway in metastatic breast cancer.
Key Findings
- Mitochondrial GSH is the most upregulated metabolite in breast cancer lung metastases versus primary tumors.
- SLC25A39 loss blocks lung metastasis in three cell line models and patient-derived xenograft organoids without affecting primary tumor growth.
- Mitochondrial GSH synthesis via mito-GshF fully rescues metastatic capacity of SLC25A39 knockout cells.
- ATF4, a key integrated stress response transcription factor, bypasses SLC25A39 loss and requires mitochondrial GSH for optimal activation.
- Higher SLC25A39 expression in patient breast tumors correlates with significantly worse overall survival.
Methodology
The study combined in vivo mitochondrial metabolomics (immunoprecipitable mitotag), custom CRISPR loss-of-function and activation screens, multiple syngeneic and xenograft mouse metastasis models, patient-derived xenograft organoids, spatial metabolomics, doxycycline-inducible knockdown, and clinical IHC with survival analysis to comprehensively dissect SLC25A39 function in metastasis.
Study Limitations
All in vivo experiments used immunocompromised or syngeneic mouse models, which may not fully capture human tumor-immune interactions. The exact molecular mechanism linking mitochondrial GSH to ATF4 activation requires further elucidation. Spatial metabolomics was descriptive and the causal role of GSH enrichment in specific microenvironments remains to be fully defined.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.